FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100517526> ?p ?o ?g. }

• W2100517526 endingPage "45" @default.
• W2100517526 startingPage "4539" @default.
• W2100517526 abstract "Full oral chemotherapy (CT) is an active and convenient therapeutic option for patients with advanced breast cancer (ABC). In this retrospective analysis, we reviewed the characteristics and the outcome of patients treated by oral vinorelbine either as a single-agent or in combination with capecitabine as first- or second-line CT in the metastatic setting.We analysed 216 patients with ABC who started treatment with a full oral CT at 13 centers and seven countries between 2006 and 2008. To be eligible, patients must have received either as a first-(56%) or second-line (44%) therapy oral vinorelbine as a single-agent (54%) or in combination with capecitabine (46%).Main patients' characteristics in the full population (n=216): median age (range): 61 (32-87) years; categories of age: <50 years: 18%, 50-65 years: 44%, ≥ 65 years: 38%; hormone receptor-positive: 63%; ≥ 2 metastatic sites: 58%; visceral metastases: 49%; prior CT: 86%; prior CT for ABC: 44%; prior anthracycline treatment: 69%; prior taxane treatment: 43%, prior anthracycline plus taxane: 38%; prior endocrine therapy: 63%. Median number of cycles: 6 (range=1-54); 48% of patients received more than 6 cycles. G3/4 toxicities: neutropenia 8%, anaemia 2%, thrombocytopenia 1%, febrile neutropenia/neutropenic infection 2%, nausea 6%, vomiting 4%, diarrhea 6%, fatigue 6%, hand-foot syndrome 14% (combination with capecitabine), neuropathy 1%, alopecia (grade 2) 1%.disease control was achieved in 77% of patients [95% confidence interval=71-83%], 74% as single-agent, 81% in combination, 82% in first-line, 71% in second-line. Median progression-free survival was 9.7 months [95% confidence interval=8.2-12.6 months] in first-line and 6.6 months [95% confidence interval=5.5-8.5 months] in second-line therapy. Caregivers described these oral regimens as convenient (81%), well-tolerated (84%) and with a good compliance by patients (76%).These data from everyday practice confirm, as shown in different clinical trials, that oral vinorelbine is an active and well-tolerated CT for ABC, either as a first- or second-line in patients pre-treated with anthracyclines or taxanes. The convenience of its oral administration in association with its good tolerance profile, allows for continuation of treatment until disease progression without a pre-planned maximum of cycles." @default.
• W2100517526 created "2016-06-24" @default.
• W2100517526 creator A5000003902 @default.
• W2100517526 creator A5000993037 @default.
• W2100517526 creator A5010293363 @default.
• W2100517526 creator A5039016022 @default.
• W2100517526 creator A5041795380 @default.
• W2100517526 creator A5046350905 @default.
• W2100517526 creator A5048706345 @default.
• W2100517526 creator A5056372015 @default.
• W2100517526 creator A5060473082 @default.
• W2100517526 creator A5091709287 @default.
• W2100517526 date "2012-10-01" @default.
• W2100517526 modified "2023-10-17" @default.
• W2100517526 title "Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy." @default.
• W2100517526 cites W1905936368 @default.
• W2100517526 cites W1980810555 @default.
• W2100517526 cites W1981454586 @default.
• W2100517526 cites W1986128686 @default.
• W2100517526 cites W2009949204 @default.
• W2100517526 cites W2015159040 @default.
• W2100517526 cites W2022917890 @default.
• W2100517526 cites W2025504439 @default.
• W2100517526 cites W2037131562 @default.
• W2100517526 cites W2050582545 @default.
• W2100517526 cites W2063775957 @default.
• W2100517526 cites W2115428190 @default.
• W2100517526 cites W2115901621 @default.
• W2100517526 cites W2125930061 @default.
• W2100517526 cites W2135378470 @default.
• W2100517526 cites W2139582914 @default.
• W2100517526 cites W2142102721 @default.
• W2100517526 cites W2147839112 @default.
• W2100517526 cites W2148858542 @default.
• W2100517526 cites W2153072711 @default.
• W2100517526 cites W2165999332 @default.
• W2100517526 cites W2169518833 @default.
• W2100517526 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23060583" @default.
• W2100517526 hasPublicationYear "2012" @default.
• W2100517526 type Work @default.
• W2100517526 sameAs 2100517526 @default.
• W2100517526 citedByCount "1" @default.
• W2100517526 countsByYear W21005175262019 @default.
• W2100517526 crossrefType "journal-article" @default.
• W2100517526 hasAuthorship W2100517526A5000003902 @default.
• W2100517526 hasAuthorship W2100517526A5000993037 @default.
• W2100517526 hasAuthorship W2100517526A5010293363 @default.
• W2100517526 hasAuthorship W2100517526A5039016022 @default.
• W2100517526 hasAuthorship W2100517526A5041795380 @default.
• W2100517526 hasAuthorship W2100517526A5046350905 @default.
• W2100517526 hasAuthorship W2100517526A5048706345 @default.
• W2100517526 hasAuthorship W2100517526A5056372015 @default.
• W2100517526 hasAuthorship W2100517526A5060473082 @default.
• W2100517526 hasAuthorship W2100517526A5091709287 @default.
• W2100517526 hasConcept C121608353 @default.
• W2100517526 hasConcept C126322002 @default.
• W2100517526 hasConcept C141071460 @default.
• W2100517526 hasConcept C143998085 @default.
• W2100517526 hasConcept C2775930923 @default.
• W2100517526 hasConcept C2776694085 @default.
• W2100517526 hasConcept C2776802502 @default.
• W2100517526 hasConcept C2777063308 @default.
• W2100517526 hasConcept C2777511904 @default.
• W2100517526 hasConcept C2777909004 @default.
• W2100517526 hasConcept C2778239845 @default.
• W2100517526 hasConcept C2778850193 @default.
• W2100517526 hasConcept C2780350996 @default.
• W2100517526 hasConcept C2908647359 @default.
• W2100517526 hasConcept C526805850 @default.
• W2100517526 hasConcept C530470458 @default.
• W2100517526 hasConcept C71924100 @default.
• W2100517526 hasConcept C90924648 @default.
• W2100517526 hasConcept C99454951 @default.
• W2100517526 hasConceptScore W2100517526C121608353 @default.
• W2100517526 hasConceptScore W2100517526C126322002 @default.
• W2100517526 hasConceptScore W2100517526C141071460 @default.
• W2100517526 hasConceptScore W2100517526C143998085 @default.
• W2100517526 hasConceptScore W2100517526C2775930923 @default.
• W2100517526 hasConceptScore W2100517526C2776694085 @default.
• W2100517526 hasConceptScore W2100517526C2776802502 @default.
• W2100517526 hasConceptScore W2100517526C2777063308 @default.
• W2100517526 hasConceptScore W2100517526C2777511904 @default.
• W2100517526 hasConceptScore W2100517526C2777909004 @default.
• W2100517526 hasConceptScore W2100517526C2778239845 @default.
• W2100517526 hasConceptScore W2100517526C2778850193 @default.
• W2100517526 hasConceptScore W2100517526C2780350996 @default.
• W2100517526 hasConceptScore W2100517526C2908647359 @default.
• W2100517526 hasConceptScore W2100517526C526805850 @default.
• W2100517526 hasConceptScore W2100517526C530470458 @default.
• W2100517526 hasConceptScore W2100517526C71924100 @default.
• W2100517526 hasConceptScore W2100517526C90924648 @default.
• W2100517526 hasConceptScore W2100517526C99454951 @default.
• W2100517526 hasIssue "10" @default.
• W2100517526 hasLocation W21005175261 @default.
• W2100517526 hasOpenAccess W2100517526 @default.
• W2100517526 hasPrimaryLocation W21005175261 @default.
• W2100517526 hasRelatedWork W1985608906 @default.
• W2100517526 hasRelatedWork W2025504439 @default.

• next